This guide sets out the established eligibility framework for licensed semaglutide, BMI thresholds with weight-related conditions, in adults, used alongside diet and activity, and why eligibility is always confirmed by a clinician. It is grounded in the UK-licensed injection and NICE, and it explains the framework rather than the pill's own UK criteria, which would come from its licence.
Why the pill's UK eligibility isn't set yet
The Wegovy pill's UK eligibility is not yet defined, because it is not yet UK-licensed 3. Eligibility for a medicine is set by its licence and, for NHS use, by NICE, and for the pill those do not yet exist in the UK 34.
So this guide does not state specific eligibility criteria for the pill as UK fact 3. What it can usefully do is explain how eligibility works for licensed semaglutide, which is a fair indication of the kind of framework that would apply to an oral form once approved 14.
The honest position, as with dose and results, is that the specifics would come from the pill's UK licence and NICE assessment once approved, and a clinician would apply them 3. Until then, the established framework for the licensed medicines is the useful reference 1.
How eligibility works for licensed semaglutide
For the licensed semaglutide, eligibility for weight management centres on BMI thresholds together with weight-related health conditions, rather than being open to anyone wanting to lose weight 14. NICE sets defined criteria for NHS access, and the licence defines who the medicine is for 4.
In broad terms, that means a higher BMI, or a slightly lower BMI accompanied by a weight-related condition, used alongside a reduced-calorie diet and increased physical activity14. The exact thresholds are specific and can be updated, which is why a clinician checks them against your situation 4.
This framework reflects that these are medicines for managing overweight and obesity in people who meet clinical criteria, within a supported approach, rather than general-purpose slimming aids 14. Our guide on NICE TA875 for Wegovy explains the NHS criteria for the licensed injection 4.
An adults-only medicine
Licensed semaglutide for weight management is for adults1. This is an important point for any semaglutide weight-management product, and a fair expectation for the pill, that it would be an adult treatment rather than one for children or adolescents 13.
The reason is that eligibility and safety are established for the populations a medicine has been assessed in, and weight-management semaglutide is assessed and licensed for adults 1. Any use outside that would be beyond the licence 1.
So whatever the pill's precise UK criteria turn out to be, an adult-only constraint is the reasonable expectation, consistent with the licensed injection 13. The specifics, as ever, would come from its UK licence once approved 3.
Want to know when the Wegovy pill (oral semaglutide) becomes available in the UK? It is not yet licensed here, but you can join the waitlist to be notified, and explore the licensed options with a Cloud Pharmacy clinician in the meantime.
Eligibility is confirmed by a clinician
However eligibility is framed, the key point is that it is confirmed by a clinician, not self-assessed from a summary 1. A proper assessment checks your BMI, weight-related conditions, medical history and suitability before any weight-loss medicine is prescribed 1.
This is part of why these are prescription-only medicines: the assessment is a safeguard that makes sure the medicine is appropriate for you and that there are no reasons it should be avoided 12. Eligibility on paper is only the start; suitability is a clinical judgement 1.
So even once the pill is licensed, whether it is right for you would be a decision made with a prescriber through a proper consultation, not something to assume from meeting a BMI number 12. Our guide on a good online consultation explains what that assessment should cover 2.
How the pill might fit alongside the injection
If the pill is licensed, it would most likely sit alongside the licensed injection as another option within a similar eligibility framework, rather than for a completely different group 13. Both are semaglutide for weight management, so the broad population they serve would be expected to overlap 1.
What an oral option could add is choice, particularly for people who would prefer a tablet to an injection, within whatever eligibility its licence sets 13. It would not necessarily widen who is eligible; it would add a form 3.
But this is an expectation based on the licensed injection, not a statement of the pill's UK criteria, which would be confirmed by its licence and NICE 34. A clinician would advise on which option, if any, suits you once both are available 12.
The honest bottom line on eligibility
The honest bottom line is that the Wegovy pill's UK eligibility is not yet set, because it is not yet UK-licensed, so this guide explains the established framework for licensed semaglutide rather than the pill's own criteria 34. That framework centres on BMI thresholds with weight-related conditions, in adults, alongside diet and activity 14.
Whatever the pill's precise criteria turn out to be, eligibility would be confirmed by a clinician through a proper assessment, not self-assessed, and the specifics would come from its UK licence and NICE once approved 13. That is the reliable source 3.
Until then, if you want to know whether a licensed weight-loss medicine is right for you, the useful step is a proper assessment with a prescriber against the current criteria 12. Our guide on choosing a treatment covers the licensed options 1.
Why eligibility criteria exist
It can feel frustrating that weight-loss medicines are not simply available to anyone who wants them, so it helps to understand why eligibility criteria exist 14. They are there to direct a medicine to the people most likely to benefit and for whom the balance of benefit and risk has been assessed, which is a safeguard rather than an obstacle 14.
BMI thresholds and weight-related conditions are used because that is how the trials defined the populations studied, so the licence and NICE recommendations follow that evidence 14. Prescribing within those criteria is how a medicine is used as it was assessed to be used 1.
This also explains why criteria can feel strict and why they can change over time as evidence develops 4. The current version is always the one that matters, which is another reason a clinician checks your situation against the up-to-date criteria rather than an older summary 4.
For the pill, the same logic would apply once it is licensed: its eligibility would reflect where the evidence supports its use, defined by its licence and NICE 34. Understanding this makes the eventual criteria easier to make sense of rather than feeling arbitrary 14.
What to do while the pill is awaited
If you think you might be eligible for a weight-loss medicine and want to act now, the useful step is not to wait for the pill but to have a proper assessment for the licensed options 12. A prescriber can check your eligibility against the current criteria and discuss whether a licensed medicine suits you 1.
If you would specifically prefer a tablet to an injection, that is a reasonable preference to raise, but it is worth weighing against the fact that the licensed injection is available now while the pill is not 13. A clinician can help you think that trade-off through 1.
And if you are not currently eligible for the licensed options, that is useful to know too, because it means the pill would be unlikely to change that simply by being a different form 13. Eligibility tends to follow the evidence for the medicine, not the route of administration 4.
So the most productive thing to do while the pill is awaited is to understand your own eligibility for the licensed options through a proper assessment, rather than to put plans on hold for a product that is not yet available here 12. That keeps you informed and able to act on what is actually licensed 1.
If the pill does become available and you would prefer it, that conversation can happen then, against its actual UK eligibility and with a clinician who knows your case 13. Nothing is lost by understanding your options now and revisiting them when a new licensed choice arrives, which is a far stronger position than delaying in the hope of a product whose UK availability and criteria are not yet confirmed 12. Acting on what is licensed today, while staying open to new options, is the most practical approach 13. A prescriber can help you keep both in view as the landscape changes 12. That way you are neither waiting on something unconfirmed nor missing out on what could help you now 1.
Frequently asked questions
Who will be eligible for the Wegovy pill?
Its UK eligibility is not yet set, because it is not yet UK-licensed; that would come from its licence and NICE once approved 34. For licensed semaglutide, eligibility centres on BMI thresholds with weight-related conditions, in adults 14.What BMI do you need for semaglutide?
For the licensed medicines, eligibility involves a higher BMI, or a slightly lower BMI with a weight-related condition, alongside diet and activity 14. The exact thresholds are specific and checked by a clinician against your situation 4.Is the Wegovy pill for adults only?
Licensed semaglutide for weight management is for adults, so an adult-only constraint is the fair expectation for the pill 13. The precise criteria would come from its UK licence once approved 3.Can I check my own eligibility?
Eligibility is confirmed by a clinician through a proper assessment of your BMI, weight-related conditions, history and suitability, not self-assessed 1. Meeting a BMI number is only the start; suitability is a clinical judgement 12.Would the pill be for different people than the injection?
Most likely it would sit alongside the injection within a similar framework, adding a tablet option rather than widening who is eligible 13. Its precise UK criteria would come from its licence and NICE 34.How do I find out if a weight-loss medicine is right for me?
Have a proper assessment with a prescriber against the current criteria for the licensed options 12. That is more reliable than self-assessing, and it is how suitability is properly judged 1.Your next step
The Wegovy pill's UK eligibility is not yet set, because it is not yet UK-licensed, so this guide explains the established framework for licensed semaglutide rather than the pill's own criteria. That framework centres on BMI thresholds together with weight-related health conditions, in adults, used alongside a reduced-calorie diet and increased physical activity, with the exact thresholds defined by the licence and, for NHS use, by NICE.
An adult-only constraint is a fair expectation for the pill, and if licensed it would most likely sit alongside the injection within a similar framework, adding a tablet option rather than widening who is eligible. Whatever the precise criteria turn out to be, eligibility would be confirmed by a clinician through a proper assessment, not self-assessed, and the specifics would come from the pill's UK licence and NICE once approved. Until then, a proper assessment with a prescriber against the current criteria is the useful step.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References
- Wegovy SmPC 4.1/4.2 (licensed INJECTION: weight-management indication in adults meeting BMI/comorbidity criteria; adjunct to reduced-calorie diet and increased physical activity; assessment-based, prescription-only; used to explain the established framework, NOT the pill's own UK criteria)
- Semaglutide (prescription-only; assessment; registered pharmacy; general framing)
- General UK framing; Wegovy pill not UK-licensed (June 2026); its eligibility would be set by its UK licence and NICE; no pill-specific criteria asserted
- NICE TA875 (semaglutide for managing overweight and obesity: BMI + weight-related comorbidity criteria; within a structured/specialist service for NHS access; defined eligibility framework for the licensed injection)
